当前蛋白身份:P48729 重新检索
本组结构的主要差异维度
构建体不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
5FQD Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase 提交 2015-12-09 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–337(337 aa)
未记录 ZN ZINC ION × 1 LVY S-Lenalidomide × 1 X-RAY DIFFRACTION
X-ray结晶条件 70 MM TRIS PH 7.0 140 MM MGCL2 7% W/V PEG 8000
分辨率 2.45 Å R-free 0.210
5FQD Structural basis of Lenalidomide induced CK1a degradation by the crl4crbn ubiquitin ligase 提交 2015-12-09 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–337(337 aa)
未记录 ZN ZINC ION × 1 LVY S-Lenalidomide × 1 X-RAY DIFFRACTION
X-ray结晶条件 70 MM TRIS PH 7.0 140 MM MGCL2 7% W/V PEG 8000
分辨率 2.45 Å R-free 0.210
6GZD Crystal structure of Human CSNK1A1 with A86 提交 2018-07-03 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 1–337(337 aa)
未记录 DMS DIMETHYL SULFOXIDE × 2 PGE TRIETHYLENE GLYCOL × 3 EDO 1,2-ETHANEDIOL × 5 PEG DI(HYDROXYETHYL)ETHER × 6 TCE 3,3',3''-phosphanetriyltripropanoic acid × 1 LCI [4-[[4-[5-(cyclopropylmethyl)-1-methyl-pyrazol-4-yl]-5-fluoranyl-pyrimidin-2-yl]amino]cyclohexyl]azanium × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8;277.15 K;CSNK1A1 at a concentration of 5.8 mg/ml (50 mM Tris-HCl, 300 mM NaCl, 0.25 mM TCEP, pH 8.0) was pre-incubated with 0.7 mM (4.7-fold molar excess) of Mg2+-ATP (120 mM in UPW) for 1 h. 0.1 uL of the protein solution was then mixed with 0.1 uL of reservoir solution (0.10 M MES/NaOH pH 6.8, 10.0% 2-propanol, 26.0% PEG400) and equilibrated at 4 C over 0.06mL of reservoir solution. Well diffracting crystals appeared within 4 days and grew to full size over 23 days.
分辨率 2.28 Å R-free 0.221
7WTT Cryo-EM structure of a human pre-40S ribosomal subunit - State RRP12-A1 (with CK1) 提交 2022-02-05 Assembly 1 蛋白–RNA 异源复合物;蛋白 × 33 PDB 声明:34-meric(34) 与全部聚合物一致
链 a 1–337(337 aa)
未记录 SAH S-ADENOSYL-L-HOMOCYSTEINE × 1 ZN ZINC ION × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7.4
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.10 Å
8G66 Structure with SJ3149 提交 2023-02-14 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 1–337(337 aa)
未记录 ZN ZINC ION × 1 YOT (3S)-3-{5-[(1,2-benzoxazol-3-yl)amino]-1-oxo-1,3-dihydro-2H-isoindol-2-yl}piperidine-2,6-dione × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;70 MM TRIS PH 7.0, 140 MM MGCL2, 7% W/V PEG 8000
分辨率 3.45 Å R-free 0.272
8G66 Structure with SJ3149 提交 2023-02-14 Assembly 2 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 F 1–337(337 aa)
未记录 ZN ZINC ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293.15 K;70 MM TRIS PH 7.0, 140 MM MGCL2, 7% W/V PEG 8000
分辨率 3.45 Å R-free 0.272
9OTY DDB1-CRBN with CK1 alpha, SB-405483, and DEG-47: composite map and model submission 提交 2025-05-27 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 C 10–303(294 aa)
未记录 ZN ZINC ION × 1 A1CEH N-{2-[(3R)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}benzamide × 1 A1CEG N-[3-(benzyloxy)pyridin-2-yl]-N'-(4-cyano-2-hydroxyphenyl)urea × 1 ELECTRON MICROSCOPY
cryo-EM缓冲液 pH 7;10mM HEPES, 240mM NaCl, 3mM TCEP
cryo-EM玻璃化条件 冷冻剂 ETHANE
分辨率 3.00 Å